Australia weighs "major asthma burden"
This article was originally published in Clinica
Asthma is expected to continue to "rank as one of the major causes of disease burden in Australia for the next two decades, particularly among females", according to the government's health protection agency, the Australian Institute of Health and Welfare (AIHW).
You may also be interested in...
A safety study of Pfizer's anchor immunology brand Xeljanz showed higher rates of heart attacks and cancer versus a TNF inhibitor.
The app allegedly shared sensitive customer information with three China-based data analysis and collection firms.
Among four FDA regulatory items withdrawn from OMB review is “Cannabidiol Enforcement Policy; Draft Guidance for Industry,” which the agency submitted in July 2020.